Ralaniten triacetate

• CAT Number: I014809
• CAS Number: 1637573-04-6
• Molecular Formula: C27H33ClO8
• Molecular Weight: 521.00
• Purity: ≥95%
• Synonyms: [(2S)-2-acetyloxy-3-[4-[2-[4-[(2S)-2-acetyloxy-3-chloropropoxy]phenyl]propan-2-yl]phenoxy]propyl] acetate
• InChI: InChI=1S/C27H33ClO8/c1-18(29)32-16-26(36-20(3)31)17-34-24-12-8-22(9-13-24)27(4,5)21-6-10-23(11-7-21)33-15-25(14-28)35-19(2)30/h6-13,25-26H,14-17H2,1-5H3/t25-,26-/m1/s1
• InChIKey: HGHVYYKTOXUQNT-CLJLJLNGSA-N
• SMILES: CC(=O)OC[C@H](COC1=CC=C(C=C1)C(C)(C)C2=CC=C(C=C2)OC[C@@H](CCl)OC(=O)C)OC(=O)C

Ralaniten triacetate (Cat No.:I014809) is an oral prodrug of ralaniten, a first-in-class small-molecule inhibitor that directly targets the N-terminal domain of the androgen receptor (AR). Unlike conventional antiandrogens that bind to the ligand-binding domain, ralaniten triacetate blocks AR-driven transcription even in the presence of resistance-conferring mutations or splice variants such as AR-V7. It has been investigated in clinical trials for metastatic castration-resistant prostate cancer (mCRPC), showing potential in overcoming treatment resistance and expanding therapeutic strategies in advanced prostate cancer management.